Are clinical trials representative of a broader patient population?

Sarah Anwar, MDLinx

San Antonio Breast Cancer Symposium 2017

San Antonio, Texas, United States | December 05-09, 2017

In clinical trials for cancer drug development, researchers have been enrolling patients who are otherwise healthy; patients who are asymptomatic, and have free mobility. By doing this they can “isolate” the cancer to ensure that symptoms and complications are not due to other underlying conditions.

According to Tatiana Prowell, MD, breast cancer scientific liaison, FDA Oncology Center of Excellence, assistant professor of oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, however, the challenge with this, is that, more often than not, everyday cancer patients aren’t generally healthy and asymptomatic.

“There are other groups that I think we’ve excluded in the past, too. So, that would include patients with metastatic involvement of the central nervous system, brain metastases. It would include patients at extremes of age in either directions. Historically, some trials limited patients are over 70 who weren’t able to enroll. Pediatric patients weren’t able to enroll,” said Dr. Prowell.

“This resulted in clinical trials that took longer to accrue [and] gave us results that were less generalizable to the sorts of patients that would be treated.”

However, more recently, there’s been a move to make clinical trials more representative of a wider cancer population.

All Interviews

From this Conference

4:40

Implementing the TEAM approach to optimize concurrent palliative care
Oncologists should be open to implementing the TEAM approach to provide their patients the best concurrent palliative care possible, Thomas J. Smith, MD, FACP, FASCO, FAAHPM,...
Thomas J. Smith, MD, FACP, FASCO, FAAHPM
2:34

Estrogen receptor expression in luminal tumors & recurrence and metastasis
Luminal breast cancer subtypes are characterized by estrogen-receptor and estrogen-related genes, which sets them apart from other tumors that are not hormonally driven.
Angela DeMichele, MD, MSCE
2:36

A look back at SABCS 2017: Overtreatment can result in lifelong complications
Researchers from around the world gathered at the 2017 San Antonio Breast Cancer Symposium to present research that would change the way we view breast cancer.
Sheldon Feldman, MD, FACS

2:14

Breast cancer: Where we were and how far we’ve come
Over the past few decades, great progress has been made in the field of breast cancer, according to Tatiana Prowell, MD, breast cancer scientific liaison, FDA Oncology Center...
Tatiana Prowell, MD
7:15

Seamless designs for clinical trials: A new wave in drug development, explained
With the movement toward developing more targeted therapies, the FDA has updated its drug development system to include what they have designated as ‘seamless...
Tatiana Prowell, MD
1:15

The paradoxical role of family history in breast cancer risk
Although family history can influence a patient’s risk of developing breast cancer, it does not increase that risk once other risk factors are identified.
Amy C. Degnim, MD

This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium 2017.